IMUX
Income statement / Annual
Last year (2025), Immunic Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Immunic Inc's net income was -$97.17 M.
See Immunic Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$6.32 K |
| Cost of Revenue |
$168.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$50.00 K
|
$15.00 K
|
$998.00 K
|
$1.81 M
|
| Gross Profit |
-$168.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$50.00 K
|
-$15.00 K
|
-$998.00 K
|
-$1.80 M
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-285.3
|
| Research and Development Expenses |
$81.98 M
|
$80.05 M
|
$83.22 M
|
$71.26 M
|
$61.12 M
|
$38.64 M
|
$22.51 M
|
$24.83 M
|
$39.34 M
|
$30.05 M
|
| General & Administrative Expenses |
$21.25 M
|
$18.01 M
|
$16.01 M
|
$15.26 M
|
$13.30 M
|
$10.33 M
|
$14.52 M
|
$13.59 M
|
$13.31 M
|
$11.22 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$21.25 M
|
$18.01 M
|
$16.01 M
|
$15.26 M
|
$13.30 M
|
$10.33 M
|
$14.52 M
|
$13.59 M
|
$13.31 M
|
$11.22 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$32.97 M
|
$17.25 M
|
$0.00
|
$0.00
|
$28.00 K
|
$0.00
|
$297.00 K
|
| Operating Expenses |
$103.23 M
|
$98.05 M
|
$99.22 M
|
$119.49 M
|
$91.67 M
|
$48.97 M
|
$37.03 M
|
$38.41 M
|
$52.66 M
|
$41.27 M
|
| Cost And Expenses |
$103.23 M
|
$98.05 M
|
$99.22 M
|
$119.49 M
|
$91.67 M
|
$48.97 M
|
$37.03 M
|
$38.41 M
|
$52.66 M
|
$41.27 M
|
| Interest Income |
$1.04 M
|
$3.39 M
|
$3.08 M
|
$1.04 M
|
$66.00 K
|
$58.00 K
|
$107.00 K
|
$521.00 K
|
$650.00 K
|
$284.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$1.04 M
|
$0.00
|
$0.00
|
$107.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$168.00 K
|
$134.00 K
|
$111.00 K
|
$77.00 K
|
$85.00 K
|
$39.00 K
|
$50.00 K
|
$15.00 K
|
$998.00 K
|
$1.81 M
|
| EBITDA |
-$97.00 M |
-$97.92 M |
-$99.11 M |
-$86.44 M |
-$91.58 M |
-$48.93 M |
-$36.98 M |
-$15.14 M |
-$51.08 M |
-$39.16 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-6201.15
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-6534.48
|
| Total Other Income/Expenses Net |
$6.06 M
|
-$2.46 M
|
$5.61 M
|
-$919.00 K
|
-$1.28 M
|
$4.95 M
|
$2.10 M
|
$455.00 K
|
$577.00 K
|
$297.00 K
|
| Income Before Tax |
-$97.17 M
|
-$100.51 M
|
-$93.61 M
|
-$120.41 M
|
-$92.95 M
|
-$44.02 M
|
-$34.93 M
|
-$41.48 M
|
-$52.08 M
|
-$40.97 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-6487.45
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$549.00 K
|
$0.00
|
$0.00
|
| Net Income |
-$97.17 M
|
-$100.51 M
|
-$93.61 M
|
-$120.41 M
|
-$92.95 M
|
-$44.02 M
|
-$34.83 M
|
-$41.48 M
|
-$52.08 M
|
-$40.97 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-6487.45
|
| EPS |
-6.24 |
-10 |
-21.1 |
-37.8 |
-39.2 |
-28.1 |
-45.1 |
-391.6 |
-522.6 |
-522.1 |
| EPS Diluted |
-6.24 |
-10 |
-21.1 |
-37.8 |
-39.2 |
-28.1 |
-45.1 |
-391.6 |
-522.6 |
-522.1 |
| Weighted Average Shares Out |
$15.57 M
|
$10.02 M
|
$4.43 M
|
$3.18 M
|
$2.37 M
|
$1.57 M
|
$772.23 K
|
$105.92 K
|
$99.65 K
|
$78.47 K
|
| Weighted Average Shares Out Diluted |
$15.57 M
|
$10.02 M
|
$4.43 M
|
$3.18 M
|
$2.37 M
|
$1.57 M
|
$772.23 K
|
$105.92 K
|
$99.65 K
|
$78.47 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
